Aphria (TSE:APHA) had its price target reduced by Pi Financial from C$9.00 to C$8.00 in a research note issued to investors on Wednesday, BayStreet.CA reports. They currently have a buy rating on the stock.
A number of other brokerages also recently commented on APHA. Eight Capital decreased their target price on Aphria from C$11.00 to C$9.00 in a research note on Wednesday, October 16th. Cormark decreased their target price on Aphria from C$14.00 to C$8.00 in a research note on Wednesday, October 16th. CIBC upgraded Aphria from an underperform rating to a neutral rating and lifted their target price for the company from C$6.50 to C$7.00 in a research note on Wednesday. Finally, Jefferies Financial Group decreased their target price on Aphria from C$15.00 to C$11.00 in a research note on Friday, October 11th.
APHA stock traded down C$0.18 during midday trading on Wednesday, reaching C$6.70. The company had a trading volume of 3,365,547 shares, compared to its average volume of 3,955,271. The company has a quick ratio of 4.20, a current ratio of 5.99 and a debt-to-equity ratio of 27.00. The stock has a 50 day moving average price of C$6.50 and a 200 day moving average price of C$7.66. Aphria has a fifty-two week low of C$4.95 and a fifty-two week high of C$14.37. The firm has a market capitalization of $1.70 billion and a PE ratio of -78.82.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
See Also: Do You Need a Fiduciary?
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.